Vysov-M 50/500mg (Vildagliptin/Metformin)

Overview

Vysov-M 50/500mg is an effective oral medication for treating diabetes that incorporates two agents that complement each other: Vildagliptin (50 mg) and Metformin Hydrochloride (500 mg). The combination of fixed doses is recommended for the treatment of Type 2 Diabetes Mellitus (T2DM) in adults, specifically for patients with blood sugar levels not adequately controlled with metformin or any other monotherapies. It works by stimulating the production of insulin, decreasing the production of glucose in the liver, as well as increasing the body’s sensitivity to insulin and helping patients attain more effective glycemic control.

Composition

• Vildagliptin – 50 mg
• Metformin Hydrochloride (as extended-release or immediate release, depending on formulation) – 500 mg
• Form: Oral tablet
• Manufacturer: Cipla Limited

Indications

Vysov-M 50/500mg can be used as an aid to fitness and diet:

• Adults who suffer from Type 2 Diabetes Mellitus with blood sugar levels that are not adequately managed with metformin on its own.
• Patients who were previously treated using distinct tablets consisting of Vildagliptin and Metformin wish to make their regimen simpler.
• In conjunction with the dual therapy, or when used in conjunction with other agents to treat diabetes under the supervision of a medical professional.

Note: The medicine is not recommended to be used in patients suffering from the condition of Type 1 Diabetes Mellitus or to treat ketoacidosis in diabetics.

Mechanism of Action

Vysov-M is a combination of two anti-diabetic agents using distinct and mutually beneficial mechanisms:

Vildagliptin (DPP-4 Inhibitor):

• Blocks the enzyme dipeptidyl peptidase-4 (DPP-4), which reduces the incretin hormones (GLP-1 and GIP).
• Incretins boost insulin production from beta cells. They also inhibit the release of glucagon from alpha cells inside the pancreas, in a way that is glucose-dependent.
• This results in improved postprandial (after dinner) and fasting blood glucose control, without creating the most common cases of hypoglycemia.

Metformin (Biguanide):

• Decreases hepatic glucose production (gluconeogenesis).
• It increases insulin sensitivity and increases the uptake of glucose in the peripheral blood.
• Beneficial impacts can have beneficial effects on Lipid profiles and could help with managing weight.

When used together, Vildagliptin and Metformin offer a synergistic result on glycemic control.

Clinical Benefits

• Enhanced Glycemic Control: A superior reduction in HbA1c when compared with monotherapy.
• Low Risk of Hypoglycemia: Through the glucose-dependent mechanism of Vildagliptin.
• Weight Neutrality: In contrast to insulin or sulfonylureas, Vysov-M is usually weight-neutral.
• Convenient Dosing: Fixed-dose combination improves patient compliance.
• Cardiometabolic Benefits: Metformin is known to have cardiovascular advantages; Vildagliptin has shown neutral impacts on outcomes for cardiac patients.

Dosage and Administration

• A typical dose for starting will be just one tablet Vysov-M 50/500mg twice a day (once at the beginning of each morning and at night).
• Dosage can vary depending upon the current condition of the patient or renal function, as well as the individual’s tolerance.
• Tablets are best taken during meals in order to minimize gastrointestinal consequences of metformin.
• Limit your dosage to the recommended dose for a day in the range of 100 mg of Vildagliptin as well as 2000mg of Metformin.

Follow your physician’s advice. Never alter the dosage without contacting your doctor.

Precautions and Warnings

Renal Function:

Metformin is excreted through the kidneys. Its accumulation could cause lactosis, which is a very rare but severe complication.

Continuous monitoring of renal function (eGFR and blood creatinine) is crucial.

Do not recommend for patients who have eGFR < 30 mL/min/1.73 m².

Hepatic Impairment:

Vildagliptin should not be used for those suffering from liver disease or high liver enzymes.

Check the liver’s function regularly.

Cardiovascular Risk:

Be cautious of patients who have a history of heart failure.

Vysov-M cannot be used as a replacement for insulin treatment in patients who require strict glycemic control.

Alcohol Use:

Excessive alcohol consumption is recommended due to the higher risk of developing lactic acidosis.

Surgery and Radiological Procedures:

Do not discontinue metformin until you have completed any major surgical procedure or Iodinated Contrast imaging techniques.

Contraindications

• The hypersensitivity is noted in the past to Vildagliptin, Metformin, or any of the excipients.
• End-stage renal impairment or severe kidney disease.
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis.
• History of lactic acidosis.

Possible Side Effects

Similar to all drugs, Vysov-M can cause adverse reactions in people with certain conditions. Some of the most common side effects include:

Gastrointestinal:

• Nausea
• Diarrhea
• Abdominal discomfort
• Flatulence
• Loss of appetite

Metabolic:

• Hypoglycemia (more common when used with sulfonylureas or insulin)

Other:

• Headache
• Dizziness
• Taste disturbance (metallic taste)
• Elevated liver enzymes
• Skin reactions (rash, pruritus)

Take immediate medical care if you are experiencing indications of an acidic lactic condition. Symptoms include rapid or intense breathing, intense muscle pain, fatigue, or uncharacteristic drowsiness.

Drug Interactions

• Cimetidine could increase the levels of metformin.
• Be cautious with hypoglycemic medications to prevent an increase in blood sugar levels.
• Beware of alcohol and other drugs, which can affect kidney function (e.g., NSAIDs, diuretics).

Be sure to inform your doctor regarding any medication or supplements you are taking, as well as herbal items you’re taking.

Use in Special Populations

• Pregnancy: Only use if necessary and required. Limited human data available.
• Lactation: The safety of breastfeeding infants is not well-established.
• Pediatric Use: The safety and effectiveness of this product are not known at a young age.
• Elderly: Beware of the possibility of kidney impairment as well as lactosis.

Storage Instructions

• Place in a room that is dry and cool at a temperature of 25°C (77°F).
• Beware of the elements of moisture as well as the direct sunlight.
• Be sure to keep away from children.
• Do not use the medicine after the expiry date.

Patient Advice and Lifestyle Recommendations

• Make sure you eat a balanced and healthy diet, using food items that have a low glycemic index.
• Regularly exercise as per the physician’s recommendations.
• Keep track of your blood glucose levels according to the instructions.
• Avoid skipping or doing double doses.
• Attend regularly scheduled follow-up appointments to conduct blood tests (HbA1c, liver, kidney function).
• Take a sugar-rich food source for hypoglycemia-related symptoms.

Conclusion

Vysov-M 50/500mg is an efficient, tolerated dual oral treatment that aids patients suffering from Type 2 Diabetes Mellitus in controlling their blood sugar levels with greater efficiency. The dual action of the drug that combines the incretin-boosting actions of Vildagliptin as well as the insulin-sensitizing lower glucose effects of Metformin is a great solution for the individual treatment of patients suffering from diabetes. Utilized in conjunction with the right nutrition, exercise routine and medical supervision, the Vysov-M drug can dramatically enhance the glycemic outcome and improve the health of people with diabetes.